Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Schizophr Res ; 208: 390-396, 2019 06.
Artigo em Inglês | MEDLINE | ID: mdl-30777603

RESUMO

INTRODUCTION: A faster and more accurate self-report screener for early psychosis is needed to promote early identification and intervention. METHODS: Self-report Likert-scale survey items were administered to individuals being screened with the Structured Interview for Psychosis-risk Syndromes (SIPS) and followed at eight early psychosis clinics. An a priori analytic plan included Spectral Clustering Analysis to reduce the item pool, followed by development of Support Vector Machine (SVM) classifiers. RESULTS: The cross-validated positive predictive value (PPV) of the EPSI at the default cut-off (76.5%) exceeded that of the clinician-administered SIPS (68.5%) at separating individuals who would not convert to psychosis within 12 months from those who either would convert within 12 months or who had already experienced a first episode psychosis (FEP). When used in tandem with the SIPS on clinical high risk participants, the EPSI increased the combined PPV to 86.6%. The SVM classified as FEP/converters only 1% of individuals in non-clinical and 4% of clinical low risk populations. Sensitivity of the EPSI, however, was 51% at the default cut-off. DISCUSSION: The EPSI identifies, comparably to the SIPS but in less time and with fewer resources, individuals who are either at very high risk to develop a psychotic disorder within 12 months or who are already psychotic. At its default cut-off, EPSI misses 49% of current or future psychotic cases. The cut-off can, however, be adjusted based on purpose. The EPSI is the first validated assessment to predict 12-month psychotic conversion. An online screening system, www.eps.telesage.org, is under development.


Assuntos
Diagnóstico por Computador , Internet , Aprendizado de Máquina , Transtornos Psicóticos/diagnóstico , Diagnóstico Precoce , Humanos , Valor Preditivo dos Testes , Transtornos Psicóticos/psicologia , Medição de Risco , Máquina de Vetores de Suporte
2.
J Pharmacol Exp Ther ; 296(3): 797-805, 2001 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-11181909

RESUMO

Modulation of glutathione has been proposed as a mechanism to alter the efficacy and toxicity of chemotherapeutic agents. We investigated in vitro cytoenhancement of chemotherapy toxicity by reducing cellular glutathione levels with L-buthionine-[S,R]-sulfoximine (BSO), and chemoprotection with small molecular weight sulfur-containing agents that mimic or replace glutathione. Cytotoxicity, caspase-2 enzymatic activity, and in situ DNA staining for apoptosis were assessed in cultured human small cell lung carcinoma cells and fibroblasts. BSO treatment reduced the half-maximal cytotoxic dose of the alkylating chemotherapeutics melphalan, carboplatin, and cisplatin, and increased the total magnitude of cell death. Melphalan was more sensitive than carboplatin or cisplatin to BSO. The chemoprotective agents sodium thiosulfate, N-acetylcysteine, and glutathione ethyl ester reduced the cytotoxicity of all three alkylating chemotherapeutics regardless of BSO treatment, but D-methionine was effective only against the platinum agents. N-Acetylcysteine was the most effective protectant tested. Chemoprotection against melphalan toxicity was maximally effective only if administered concurrent with chemotherapy, whereas chemoprotection for the platinum agents remained effective if delayed 4 h after chemotherapy. BSO enhancement and N-acetylcysteine chemoprotection for melphalan toxicity occurred at least partially through an apoptotic mechanism. Modulation of glutathione levels will be valuable in the clinical setting if chemotherapy and chemoprotectant can be physically and/or temporally separated. Cytoenhancement and chemoprotection may be particularly useful in the central nervous system where the blood-brain barrier of the cerebral vasculature creates two compartments, for cytoenhancement in brain tumors and systemic chemoprotection.


Assuntos
Alquilantes/farmacologia , Apoptose , Butionina Sulfoximina/farmacologia , Tiossulfatos/farmacologia , Acetilcisteína/farmacologia , Antimetabólitos Antineoplásicos/farmacologia , Carboplatina/farmacologia , Sobrevivência Celular/efeitos dos fármacos , Citoproteção , Interações Medicamentosas , Humanos , Peso Molecular , Substâncias Protetoras/farmacologia , Fatores de Tempo , Células Tumorais Cultivadas
3.
Cognition ; 51(2): 131-76, 1994 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-8168357

RESUMO

Experiments investigated whether infants infer that a hidden, freely moving object will move continuously and smoothly. Infants aged 6 and 10 months, like the 4-month-old infants in previous experiments, inferred that the object's path would be connected and unobstructed, in accord with the principle of continuity. In contrast, 4- and 6-month-old infants did not appear to infer that the object's path would be smooth, in accord with the principle of inertia. At 8 and 10 months, knowledge of inertia appeared to be emerging but remained weaker than knowledge of continuity. These findings are consistent with the view that common sense knowledge of physical objects develops by enrichment around constant core principles.


Assuntos
Percepção de Movimento , Cognição , Feminino , Humanos , Lactente , Masculino , Estimulação Luminosa
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...